NAS:ONCT (USA)
Business Description
Oncternal Therapeutics Inc
NAICS : 325412
SIC : 2834
12230 El Camino Real, Suite 300, San Diego, CA, USA, 92130
Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2650.29 | |||||
Equity-to-Asset | 0.94 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0 | |||||
Beneish M-Score | -3.39 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 62.1 | |||||
3-Year EPS without NRI Growth Rate | 61.9 | |||||
3-Year FCF Growth Rate | 64.3 | |||||
3-Year Book Growth Rate | -38.3 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 69.66 | |||||
9-Day RSI | 61.43 | |||||
14-Day RSI | 56.18 | |||||
6-1 Month Momentum % | -42.78 | |||||
12-1 Month Momentum % | -70.71 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 16.07 | |||||
Quick Ratio | 16.07 | |||||
Cash Ratio | 15.52 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -143.2 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -37.26 | |||||
ROA % | -35.16 | |||||
ROIC % | -1279.21 | |||||
ROC (Joel Greenblatt) % | -29880.71 | |||||
ROCE % | -37.28 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.72 | |||||
Price-to-Tangible-Book | 0.72 | |||||
EV-to-EBIT | 0.48 | |||||
EV-to-EBITDA | 0.48 | |||||
EV-to-FCF | 0.58 | |||||
Price-to-Net-Current-Asset-Value | 0.72 | |||||
Price-to-Net-Cash | 0.74 | |||||
Earnings Yield (Greenblatt) % | 208.33 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:ONCT
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0 | ||
EPS (TTM) ($) | -0.71 | ||
Beta | 1.48 | ||
Volatility % | 100.11 | ||
14-Day RSI | 56.18 | ||
14-Day ATR ($) | 0.081595 | ||
20-Day SMA ($) | 1.094 | ||
12-1 Month Momentum % | -70.71 | ||
52-Week Range ($) | 0.6902 - 4.63 | ||
Shares Outstanding (Mil) | 53.21 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Oncternal Therapeutics Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |